Novartis Opts For Alliance Rather Than Acquisition With Alnylam
Signs RNAi Liver Disease Collaboration
The announcement that the Swiss giant is collaborating again with Alnylam could spark fresh speculation that the firms are moving closer to a merger – or not.
You may also be interested in...
Stock Watch: Reclassified Revenues Help Novartis's Fourth Quarter
A one-off revenue rabbit brought out of the hat may have helped Novartis's fourth-quarter sales but its analysts and investors were not impressed.
Deal Watch: J&J Begins 2022 With Trio Of Technology Alliances
Heading into the J.P. Morgan Healthcare conference, pharmas have been focusing on discovery alliances. J&J’s deals look into novel tissue-targeted drugs, ionic liquid delivery technology and cancer vaccine R&D. Lilly teams with Entos on novel methods for delivering neurology drugs.
It's Time For Novartis To Put Its Leqvio Launch Strategy To The Test
Novartis Pharmaceuticals US head Victor Bulto talks to Scrip about the launch of Leqvio; the cholesterol-lowering medicine now approved by the US FDA.